🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers

Found 33 matching trials

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

PHASE1

The principal aim of this study is to obtain safety and tolerability data w...

Status

Active Not Recruiting

Location

Clinical Pharmacology of Miami, LLC

Start Date

2025-06-27

Trial ID

NCT07119125

Treatments Being Tested

MRT-8102 Placebo

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

PHASE1

The purpose of this study is to evaluate the safety, tolerability, and drug...

Status

Recruiting

Location

CenExel ACT (Formerly Anaheim Clinical Trials; LLC)

Start Date

2025-12-23

Trial ID

NCT07283263

Treatments Being Tested

BMS-985521 Placebo

Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

PHASE1

This is a phase 1, first-in-human, randomized, double-blind, placebo-contro...

Status

Completed

Location

Scientia Clinical Research Ltd

Start Date

2021-09-27

Trial ID

NCT05112159

Treatments Being Tested

IPG1094 300 mg SAD IPG1094 600 mg SAD IPG1094 900 mg SAD IPG1094 1200 mg SAD IPG1094 600 mg MAD QD IPG1094 200 mg MAD BID IPG1094 300 mg MAD BID IPG1094 300 mg Fed-Fasted IPG1094 300 mg Fasted-Fed IPG1094 100 mg SAD

AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.

PHASE1

This trial is divided in 3 parts: FIH-SAD (Single Ascending Doses), FIH-MAD...

Status

Completed

Location

Hospital del Mar Medical Research Institute (IMIM) Neurosciences Research Program

Start Date

2021-10-01

Trial ID

NCT05170737

Treatments Being Tested

AEF0217 Placebo

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

PHASE1

This is a first in human clinical study. Part 1 of the clinical study will ...

Status

Completed

Location

Research Site

Start Date

2022-07-08

Trial ID

NCT04769869

Treatments Being Tested

AZD4604 for inhalation via DPI Placebo for AZD4604 for inhalation via DPI AZD4604 for IV administration AZD4604 for oral administration AZD4604 for inhalation via DPI

Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease

PHASE1

Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and ...

Status

Completed

Location

Eurofins Optimed

Start Date

2024-01-18

Trial ID

NCT06206824

Treatments Being Tested

Leucettinib-21

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

PHASE1

This study is the first time the new medicine CPV-104 is being tested in pe...

Status

Recruiting

Location

Medizinische Universität Wien

Start Date

2025-06-26

Trial ID

NCT07483827

Treatments Being Tested

CPV-104/Placebo CPV-104

A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers

PHASE1

The purpose of this study is to assess the safety, tolerability, and pharma...

Status

Completed

Location

Nucleus Network Pty Ltd,

Start Date

2022-02-09

Trial ID

NCT05033444

Treatments Being Tested

PRV-002 Placebo

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

PHASE1

This is a First-in-Human (FiH), randomized, two-part, dose-escalation trial...

Status

Completed

Location

Center for Vaccine Development and Global Health, 685 W. Baltimore Street

Start Date

2023-08-14

Trial ID

NCT05891236

Treatments Being Tested

MAM01 1.5 mg/kg Placebo MAM01 5 mg/kg MAM01 10 mg/kg MAM01 40 mg/kg MAM01 450 mg Placebo MAM01 5 mg/kg Control MAM01 600 mg MAM01 900 mg

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

PHASE1

GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic ...

Status

Recruiting

Location

University of the Sunshine Coast (UniSC)

Start Date

2025-07-28

Trial ID

NCT07047703

Treatments Being Tested

Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers Part B - Multiple Ascending Dose (MAD) in participants with axSpA Part C - Safety expansion cohort in participants with axSpA Part D - Randomised, placebo-controlled, expansion cohort in participants with axSpA

Previous Next